a multi-specialty healthcare company, and Spectrum Pharmaceuticals, a biopharmaceutical company, have signed an exclusive collaborative agreement for the development and commercialisation of apaziquone, an anti-neoplastic agent currently being investigated for the treatment of...
BOSTON, Oct 22 - Celgene Corp said on Thursday that its third-quarter earnings rose on higher sales of its blood cancer drugs. Net income rose to $217 million, or 46 cents a share, from $136.8...
* Access to pricey cancer drugs depends on where you live * Costs of 4,000 euros a month put some drugs out of reach * Doctors say disparity is "unbearable" BERLIN, Sept 24 - The...
Drug companies are making big profits from very small increases in cancer drug effectiveness.
*Drug similar to Velcade, but hits different target *Works against a range of tumors CHICAGO, April 8 - An experimental cancer drug made by Takeda Pharmaceutical Co showed signs of slowing tumors growth in mice...
FRANKFURT, Feb 11 - German drugmaker Bayer has taken generics supplier Cipla to court for seeking approval for a copycat version of Bayer's cancer drug Nexavar in India, Bayer said on Wednesday. Previous hearings in...
LONDON, Feb 4 - Britain's healthcare cost- effectiveness watchdog, in a partial change of heart, has decided Pfizer Inc kidney cancer drug Sutent should be available to some patients on the state-run health service. But...
LONDON, Sept 15 - AstraZeneca's cancer drug Iressa should be considered as a first-line therapy for non-smoking Asian patients who develop a common type of lung cancer, researchers said on Monday. Iressa was once viewed...
* Chemo combination trial for early-stage breast cancer * Six patients suffer congestive heart failure, no deaths * Trial participants can still take drug once informed ZURICH/BOSTON, Sept 25 - Swiss drugmaker Roche Holding AG...
* U.S. panel says toxicity risks likely outweigh benefit * Votes 14-1 against FDA approval of Yondelis NEW YORK, July 15 - A Johnson & Johnson and Zeltia SA drug for ovarian cancer should not...